Allarity Therapeutics announced its first revenue-generating contract under its new CLIA-certified laboratory services strategy, providing development and validation services to a European biotech company for a precision oncology device in the U.S. This agreement marks the commercial launch of Allarity's CLIA lab services, complementing its existing gene expression and DRP® services. The deal could lead to ongoing commercial testing and recurring revenue streams, while Allarity continues prioritizing the development of its cancer drug stenoparib. The company aims to expand its lab services to other biotech firms, especially European developers targeting U.S. markets.
Allarity Therapeutics' new commercial agreement is the subject, with Pluang's health sector market data provided as context. For readers following health stocks, here is Pluang's market snapshot as of Oct 30, 2026 18:11 WIB: out of 150 priced US health-sector stocks, 75 rose and 70 fell. Notable movers include Recursion Pharmaceuticals Inc (RXRX) at USD 4.00 with a 1-day change of -5.66% and a typical hold time of 22 days, Gilead Sciences, Inc. (GILD) at USD 174.94 up 5.63%, and AstraZeneca plc (AZN) at USD 183.79 up 5.38%, with RXRX showing a Pluang order activity of 36% Sell / 64% Buy.
As Halloween approaches, MADD Canada warns against impaired driving caused by alcohol, cannabis, or drugs, which leads to hundreds of deaths and thousands of injuries annually in Canada. The organization urges people to plan safe transportation if co...
MADD Canada warns Canadians to avoid impaired driving during Halloween, emphasizing the risks of alcohol, cannabis, and drug-related crashes that cause deaths and injuries annually. The organization urges people to plan safe rides, watch for children...
Investec Bank Plc, acting as joint broker for SThree Plc, disclosed share transactions on October 29, 2026. The bank purchased and sold 49,799 ordinary shares of SThree Plc at prices ranging between 297.5 and 306.5 per share. No derivative or option ...
Investec Bank plc, acting as joint broker for Gamma Communications Plc, disclosed its share dealings on October 29, 2026. The bank purchased 218,193 ordinary shares at prices between 1091 and 1094 pence per share and sold 160,410 shares at prices bet...
Investec Bank Plc, acting as advisor and joint broker to Advanced Medical Solutions Group Plc, disclosed its share dealings on October 29, 2026. The bank purchased 10,640 ordinary shares at a price of 282.75 per share and sold 98 shares at 283 each. ...
